Yayın:
Evaluating coagulation disorders in the use of bevacizumab for metastatic colorectal cancer by thrombelastography

Sadeleştirilmiş öğe sayfası
dc.contributor.authorZeki Üstüner
dc.contributor.authorOlga Meltem Akay
dc.contributor.authorMüge Keskin
dc.contributor.authorEsin Kuş
dc.contributor.authorCengiz Bal
dc.contributor.authorZafer Gülbaş
dc.contributor.orcid0000-0002-6759-1939
dc.contributor.orcid0000-0002-1553-2902
dc.contributor.orcid0000-0002-4709-0627
dc.date.accessioned2026-05-20T09:43:09Z
dc.date.issued2012-06-13
dc.identifier.doi10.1007/s12032-012-0274-0
dc.identifier.endpage3128
dc.identifier.issn1357-0560
dc.identifier.issue5
dc.identifier.openalexW2023015771
dc.identifier.startpage3125
dc.identifier.urihttps://hdl.handle.net/11421/38643
dc.identifier.urihttps://doi.org/10.1007/s12032-012-0274-0
dc.identifier.volume29
dc.language.isoen
dc.relation.ispartofMedical Oncology
dc.rightsrestrictedAccess
dc.subjectMedicine
dc.subjectPartial thromboplastin time
dc.subjectProthrombin time
dc.subjectBevacizumab
dc.subjectColorectal cancer
dc.subjectInternal medicine
dc.subjectFibrinogen
dc.subjectCoagulation
dc.subjectCoagulation Disorder
dc.subjectThrombin time
dc.subjectPlatelet
dc.subjectOncology
dc.subjectGastroenterology
dc.subjectChemotherapy
dc.subjectCancer
dc.subject.sdg3
dc.titleEvaluating coagulation disorders in the use of bevacizumab for metastatic colorectal cancer by thrombelastography
dspace.entity.typePublication

Dosyalar

Koleksiyonlar

Publications